Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Semin Immunol. 2015 Apr 7;27(3):200–215. doi: 10.1016/j.smim.2015.03.004

Table 3.

SPM receptors – Genetically modified mice

Receptor LM Agonist Genetic modification Actions/phenotypes References
ALX LXA4
RvD1		 Transgenic mice Accelerated resolution with LXA4 and RvD1 in peritonitis [56]
Deficient mice RvD1 action (e.g. PMN trafficking, miR and cytokine regulation) is reduced in peritonitis [56]
Deficient mice RvD1 actions (reduction of PGE2 and LTB4) is abolished in peritonitis [57]
Deficient mice Reduced protection of 15-epi-LXA4 against intimal hyperplasia after carotid ligation [190]
Deficient mice ↑ disease severity (hypothermia and cardiac dysfunction) in sepsis
↓ monocyte recruitment		 [191]
ChemR23 RvE1 Transgenic mice Potentiated RvE1 actions in:
↓ PMN in peritonitis
↓ bone loss		 [192]
Transgenic mice Heightened RvE1 response in:
↑ PMN phagocytosis of P. gingivalis
↓ PMN influx into the dorsal air pouch		 [193]
BLT1 RvE1 (partial) Deficient mice RvE1 regulation of PMN infiltration is reduced [194]